The Efficacy and Safety of Citalopram in Treatment of Depression: a Multi-Center, Open-Label Study
司天梅,舒良,丁新生,王崇顺,王维智,王晓平,文有生,朱沂,朱紫青,老洪尧,刘畅,许秀峰,陈佐明,范洪玉,周盛年,张聪沛,张宁,屈一凡,姜凤英,高政,索爱琴,唐济生,张晓庆,钱敏才,胡学强,郭田生,杨友松,蓝长安,彭国光,谭庆荣,程英
DOI: https://doi.org/10.3760/j:issn:1006-7884.2005.04.008
2005-01-01
Abstract:Objective To explore the efficacy and safety of citalopram in treating the Chinese patients with depression. Methods A multi-center, open-label study was conducted. The subjects were 5 052 patients with depression, in which 4 683 with major depressive disorder, 161 comorbid with physical diseases, 112 with comorbid obsessive-compulsory disorder, and 96 with bipolar depression. The diagnoses were made according to the CCMD-Ⅲ criteria. The trial period lasted 8 weeks, and patients were evaluated with the Hamilton Depression Rating Scale, 17 items (HAMD) at 0, 2nd, 4th, 6th and 8th week. Side effects were classified prescriptively. Results In the 5 052 cases enrolled, 42.10% were male, and the mean age was 41.0 years. A highly significant reduction on the HAMD scores were noted at weeks 2, 4, 6 and 8. The reduction on the HAMD score at weeks 8 was (81.1±16.8)%, and 3 697 cases (73.18%) were clinical remission. The significant improvement was also observed in cases with comorbid physical disease, ones with comorbid OCD, and ones with bipolar depression. The efficacy was better in the acute, younger and first-episode patients than in those chronic, older and recurrent patients. The common side effects were digestive and nervous system symptoms, which occurred at the beginning of treatment and were transient. Conclusion Citalopram is a safe and effective antidepressant drug, and has better tolerability in treating depression comorbid with other disorders.